Home » Electronics & Semiconductors » Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases
Ihren XING-Kontakten zeigen

Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases

Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.
Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer-s R&D team.”

PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag® process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag® has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.

You must be logged in to post a comment Login


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de Bloggeramt.de blogoscoop